{"id":60892,"date":"2025-03-06T22:02:54","date_gmt":"2025-03-06T21:02:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/arizona-bio-startups-earn-100k-through-flinn-foundation-entrepreneurship-program\/"},"modified":"2025-03-06T22:02:54","modified_gmt":"2025-03-06T21:02:54","slug":"arizona-bio-startups-earn-100k-through-flinn-foundation-entrepreneurship-program","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/arizona-bio-startups-earn-100k-through-flinn-foundation-entrepreneurship-program\/","title":{"rendered":"Arizona Bio Startups Earn $100K Through Flinn Foundation Entrepreneurship Program"},"content":{"rendered":"
\n

PHOENIX–(BUSINESS WIRE)–#Arizona<\/a>–Arizona bioscience companies Anuncia Medical and Macula Vision Systems have been selected from a competitive field of startups to receive funding support through the 2025 Flinn Foundation Bioscience Entrepreneurship Program.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe companies receive $100,000 in non-dilutive funding support through the Arizona Bioindustry Association<\/a>, the Foundation\u2019s nonprofit partner. In addition, they can access professional and consulting services, exclusive opportunities to engage with Arizona bioscience, business, and policy leaders, and a one-year membership on Arizona\u2019s Bioscience Roadmap Steering Committee.\n<\/p>\n

\nThe 2025 program\u2019s 10 participants \u2014 including eight companies not selected for funding \u2014 were announced Thursday, March 6, at the Flinn Foundation Bio Capital Conference<\/a> at the Creighton University Health Sciences Campus at Park Central, which is a designated city of Phoenix bioscience hub.\n<\/p>\n

\nScottsdale-based Anuncia Medical<\/a> develops improved treatment options for patients with hydrocephalus, a condition when cerebrospinal fluid builds up, causing the brain to swell.\n<\/p>\n

\n\u201cThe Anuncia Medical team is deeply grateful to the Flinn Foundation for supporting our mission to improve care for Arizona patients. Our FDA-cleared and Breakthrough Designated ReFlow\u00ae Mini Flusher helps patients at high risk for shunt failure due to catheter occlusions, often worsened by Cocci-meningitis related to Valley Fever \u2014 a major concern in Arizona. It gives patients and caregivers greater control over their care and peace of mind, enabling them to maintain catheter flow from home,\u201d said Elsa Chi Abruzzo, Anuncia Medical CEO and president.\n<\/p>\n

\nEarly data shows it can significantly reduce one of the most common, costly, and traumatic revision brain surgeries, she added.\n<\/p>\n

\n\u201cThis Flinn grant allows us to generate the high-quality, prospective clinical data needed for broader commercial adoption, further cementing Arizona as a leader in neurosurgical excellence,\u201d Abruzzo said.\n<\/p>\n

\nMacula Vision Systems<\/a> of Oro Valley is developing an automated computational microscopy solution to address critical labor shortages and provide accurate, timely information of clinical samples in every lab.\n<\/p>\n

\n\u201cBeing selected \u2026 by the Flinn Foundation Bioscience Entrepreneurship Program is both a humbling honor and an exciting milestone for us at Macula Vision Systems,\u201d said Oleg Gusyatin, Macula\u2019s CEO. \u201cThis renewed recognition not only validates our ongoing commitment to transforming clinical microscopy with our AI-powered, computational solutions, but also reinforces the confidence that industry leaders have in our vision.\u201d\n<\/p>\n

\nGusyatin said the funding will support the launch of the company\u2019s regulatory strategy in an effort to bring more cost-effective and efficient diagnostic tools to laboratories.\n<\/p>\n

\nA total of 49 companies applied for the 2025 program. Ten finalists made in-person pitches before a selection committee.\n<\/p>\n

\n\u201cArizona should be excited about the number of bioscience companies discovering innovative ways to improve our health, and the progress these companies have shown in executing their goals and mission,\u201d said Tammy McLeod, Ph.D., Flinn Foundation president and CEO.\n<\/p>\n

\nNow in its 12th cohort, the entrepreneurship program was established to support Arizona\u2019s Bioscience Roadmap goal of creating a thriving hub for bioscience entrepreneurs and startups across the state.\n<\/p>\n

\n\u201cAs we look ahead to the next iteration of Arizona\u2019s Bioscience Roadmap this year, it\u2019s gratifying to see how the current Roadmap has nurtured this kind of growth in the state,\u201d McLeod said.\n<\/p>\n

\nThe finalists not selected for funding may work with the Flinn Foundation to leverage network and advisor benefits, while also receiving a one-year membership on Arizona\u2019s Bioscience Roadmap Steering Committee<\/a> and invitations to bioscience-related events and networking opportunities.\n<\/p>\n

\nThese companies are:\n<\/p>\n